Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21626325 | 0.83 | TSHR (0.38) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL4411054 | 0.83 | CA12 (0.46) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL28635336 | 0.83 | ALDH1A1 (0.44) | ALDH1A1TSHRMAPTNPSR1GLO1 | |
| SCHEMBL2491743 | 0.82 | TSHR (0.48) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL5052633 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTNPSR1GLO1 | |
| SCHEMBL12708838 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTNPSR1GLO1 | |
| SCHEMBL4959544 | 0.78 | CA12 (0.44) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL4832633 | 0.78 | CA12 (0.44) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL11340361 | 0.76 | TSHR (0.42) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL5771982 | 0.75 | CA12 (0.41) | ALDH1A1TSHRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040738-B2 | Intermediate compounds of tamiflu, methods of preparation and uses thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | claimed |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2014-08-07 | — | — | US | claimed |
| CN-111763157-B | Chiral amino compound, preparation method and application thereof, and preparation method for preparing edoxaban intermediate from chiral amino compound | 中山大学 | 2021-10-26 | — | — | CN | disclosed |
| CN-111763157-A | Chiral amino compound, preparation method and application thereof, and preparation method for preparing edoxaban intermediate from chiral amino compound | 中山大学 | 2020-10-13 | — | — | CN | disclosed |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | UNIVERSITÉ CLERMONT AUVERGNE (FR) | 2015-10-01 | — | — | US | disclosed |
| US-9139514-B2 | Process for producing oseltamivir phosphate and intermediate compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139514-B2 | Process for producing oseltamivir phosphate and intermediate compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-2301911-B1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-9040738-B2 | Intermediate compounds of tamiflu, methods of preparation and uses thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) | 2015-02-05 | — | — | US | disclosed |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2014-08-07 | — | — | US | disclosed |
| US-5565441-A | AN N-HETEROCYCLE DERIVATIVE; ANTIARTHRITIC AGENTS; DISEASES CHARACTERIZED BY ABNORMAL PHOSPHATE AND CALCIUM METABOLISM; CHRONIC DISEASES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0347840-B1 | Phosphinic acid derivates | BANYU PHARMA CO LTD (JP) | 1995-12-27 | — | — | EP | disclosed |
| EP-0654035-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES. | UPJOHN CO (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003463-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | THE UPJOHN COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993024131-A1 | PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| EP-0272583-B1 | 5-SUBSTITUTED AMINO-4-HYDROXY-PENTENOIC ACID DERIVATIVES AND THEIR USE | Banyu Pharmaceutical Co., Ltd. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-4988681-A | Dipeptidase inhibitore; reducing renal toxicity; prevention deactivation of (carba)penem antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| US-4927565-A | HYPOTENSIVE AGENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0347840-A2 | Phosphinic acid derivates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | ALDH1A1 1007/4885TSHR 2983/4885CA12 1462/4885 |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | ALDH1A1 1007/4885TSHR 2983/4885CA12 1462/4885 |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | NNMT, FLT3, TPMT | ALDH1A1 919/4885TSHR 1123/4885CA12 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.